Flora Peyvandi / X
Jun 25, 2025, 15:23
Is the Glanzmann Era Finally Over? Flora Peyvandi on Latest Bispecific Antibodies: ISTH 2025
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
”How to solve the problem of patients with Glanzmann using a novel bispecific abs – ISTH2025”
So, has the Glanzmann era truly ended—or is it just taking a coffee break before staging a comeback?
Sutacimig, a novel bispecific antibody with dual binding of FVIIa and TLT-1, seems to actually resolve the issues with clot formation in Glanzmann!
More of the latest ISTH2025 news to be posted on Hemostasis Today.
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke